PL2939692T3 - Kompozycja szczepionki do nosa przeciw grypie - Google Patents

Kompozycja szczepionki do nosa przeciw grypie

Info

Publication number
PL2939692T3
PL2939692T3 PL13867863T PL13867863T PL2939692T3 PL 2939692 T3 PL2939692 T3 PL 2939692T3 PL 13867863 T PL13867863 T PL 13867863T PL 13867863 T PL13867863 T PL 13867863T PL 2939692 T3 PL2939692 T3 PL 2939692T3
Authority
PL
Poland
Prior art keywords
vaccine composition
influenza vaccine
nasal influenza
nasal
composition
Prior art date
Application number
PL13867863T
Other languages
English (en)
Inventor
Hideki Hasegawa
Tadaki Suzuki
Akira Ainai
Taizou Kamishita
Takashi Miyazaki
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Toko Yakuhin Kogyo Kk filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of PL2939692T3 publication Critical patent/PL2939692T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13867863T 2012-12-28 2013-10-23 Kompozycja szczepionki do nosa przeciw grypie PL2939692T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012287900 2012-12-28
EP13867863.6A EP2939692B1 (en) 2012-12-28 2013-10-23 Nasal influenza vaccine composition
PCT/JP2013/078721 WO2014103488A1 (ja) 2012-12-28 2013-10-23 経鼻インフルエンザワクチン組成物

Publications (1)

Publication Number Publication Date
PL2939692T3 true PL2939692T3 (pl) 2019-10-31

Family

ID=51020588

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13867863T PL2939692T3 (pl) 2012-12-28 2013-10-23 Kompozycja szczepionki do nosa przeciw grypie

Country Status (27)

Country Link
US (2) US20160015800A1 (pl)
EP (2) EP3566715A1 (pl)
JP (1) JP6247639B2 (pl)
KR (1) KR102071099B1 (pl)
CN (2) CN104884086A (pl)
AU (1) AU2013367751B2 (pl)
BR (1) BR112015015523B1 (pl)
CA (1) CA2894223C (pl)
CY (1) CY1122372T1 (pl)
DK (1) DK2939692T3 (pl)
ES (1) ES2731899T3 (pl)
HK (1) HK1209646A1 (pl)
HU (1) HUE044434T2 (pl)
IL (1) IL239284B (pl)
LT (1) LT2939692T (pl)
MX (1) MX371154B (pl)
MY (1) MY173503A (pl)
NZ (1) NZ708922A (pl)
PH (1) PH12015501482B1 (pl)
PL (1) PL2939692T3 (pl)
PT (1) PT2939692T (pl)
RU (1) RU2652296C2 (pl)
SG (2) SG10201705190TA (pl)
SI (1) SI2939692T1 (pl)
TR (1) TR201910293T4 (pl)
TW (1) TWI624280B (pl)
WO (1) WO2014103488A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
DK3162378T3 (da) 2014-06-25 2024-03-18 Toko Yakuhin Kogyo Kk Nasalvaccinationssystem til influenzavaccine
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
CN108289948A (zh) * 2015-11-27 2018-07-17 日东电工株式会社 口腔内给药用疫苗药物组合物和口腔内给药用疫苗药物组合物的制造方法
WO2018021889A1 (ko) * 2016-07-29 2018-02-01 주식회사 셀투인 점막용 항인플루엔자 바이러스 조성물
JP7588955B2 (ja) * 2017-10-05 2024-11-25 東興薬品工業株式会社 経鼻ｂ型肝炎ワクチン組成物およびその製造方法
US12245754B2 (en) 2019-07-03 2025-03-11 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN113117093B (zh) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 一种适用于鼻粘膜递送流感疫苗的促进剂
CN113117070A (zh) * 2019-12-31 2021-07-16 辽宁成大生物股份有限公司 一种含复合佐剂的鼻用流感疫苗温敏凝胶
AU2022401207A1 (en) 2021-12-02 2024-06-06 Toko Yakuhin Kogyo Co., Ltd. Nasal vaccine-spraying formulation for simultaneously targeting nasal mucosa and nasopharynx
AU2022423668A1 (en) * 2021-12-20 2024-07-11 Japan Institute For Health Security Vaccine adjuvant agent containing polyacrylic acid polymer and use of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
US8136703B2 (en) 2006-04-21 2012-03-20 Toko Yakuhin Kogyo Kabushiki Kaisha Fluid container and airless fluid dispensing system
DK2014305T3 (en) * 2006-04-21 2017-10-16 Toko Yakuhin Kogyo Kk SPRAYABLE GEL-SHAPED SKIN / MOSPHONE ADHESIVE AND ADMINISTRATIVE SYSTEM FOR USING THE PREPARATION
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration

Also Published As

Publication number Publication date
HK1209646A1 (en) 2016-04-08
KR102071099B1 (ko) 2020-01-29
DK2939692T3 (da) 2019-07-08
JP6247639B2 (ja) 2017-12-13
HUE044434T2 (hu) 2019-10-28
IL239284A0 (en) 2015-07-30
RU2015130634A (ru) 2017-02-01
US20160015800A1 (en) 2016-01-21
CN110038123A (zh) 2019-07-23
US20190091324A1 (en) 2019-03-28
AU2013367751A1 (en) 2015-07-09
IL239284B (en) 2020-02-27
RU2652296C2 (ru) 2018-04-25
PH12015501482A1 (en) 2015-09-21
KR20150102995A (ko) 2015-09-09
MX371154B (es) 2020-01-20
SI2939692T1 (sl) 2019-10-30
ES2731899T3 (es) 2019-11-19
BR112015015523B1 (pt) 2023-02-23
CA2894223A1 (en) 2014-07-03
JPWO2014103488A1 (ja) 2017-01-12
PT2939692T (pt) 2019-06-27
EP2939692A4 (en) 2016-07-06
PH12015501482B1 (en) 2015-09-21
MX2015008380A (es) 2016-03-15
TR201910293T4 (tr) 2019-07-22
CN104884086A (zh) 2015-09-02
CY1122372T1 (el) 2021-01-27
NZ708922A (en) 2019-10-25
AU2013367751B2 (en) 2018-02-08
EP3566715A1 (en) 2019-11-13
BR112015015523A2 (pt) 2017-07-11
WO2014103488A1 (ja) 2014-07-03
SG11201504648TA (en) 2015-07-30
SG10201705190TA (en) 2017-07-28
EP2939692B1 (en) 2019-04-24
TW201427724A (zh) 2014-07-16
EP2939692A1 (en) 2015-11-04
TWI624280B (zh) 2018-05-21
LT2939692T (lt) 2019-08-12
CA2894223C (en) 2021-04-06
MY173503A (en) 2020-01-29
AU2013367751A8 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
IL239284B (en) Nasal flu vaccine compound
IL235890A0 (en) vaccine
PL2647387T3 (pl) Kompozycja szczepionki
HUE042284T2 (hu) Inhalátor
IL235825A0 (en) inhaler
SG10201912291YA (en) Vaccine compositions
AU345543S (en) Inhaler
PT2806891T (pt) Vacinas baseadas no vírus parainfluenza 5
GB201223386D0 (en) Vaccine
ZA201300395B (en) Influenza vaccine
SG11201401137TA (en) Influenza hemagglutinin variants
ZA201500656B (en) Marker vaccine
ZA201405107B (en) Mtb-c vaccine against asthma
IL232944A0 (en) Formulation for nasal administration
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
SG11201505170WA (en) Dengue virus vaccine composition
SG11201505178VA (en) Composition for nasal application
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine